Boston Scientific (NYSE:BSX) Reaches New 12-Month Low – Time to Sell?

Boston Scientific Corporation (NYSE:BSX)’s stock price reached a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $44.05 and last traded at $44.2980, with a volume of 16759915 shares traded. The stock had previously closed at $45.29.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Jefferies kept a Buy rating on Boston Scientific and still sees upside, even after cutting its price target to $67 from $100. Piper Sandler also maintained an Overweight rating, suggesting some analysts remain constructive on the long-term story.
• Positive Sentiment: Analyst coverage continues to frame BSX as oversold with potential upside, which may help support investor confidence if the company can avoid further setbacks.
• Neutral Sentiment: Recent market commentary noted Boston Scientific has been trading well below prior levels, with investors reassessing valuation after the sharp move lower.
• Negative Sentiment: Boston Scientific disclosed a nationwide, firm-initiated recall of Orca Single Use Air/Water and Suction Valves after reports that suction buttons could stick during gastrointestinal endoscopy procedures. The FDA classified the action as a Class II recall, which raises quality-control and regulatory concerns.
• Negative Sentiment: The recall adds to investor worries that even smaller accessory-device issues can hurt operations, increase oversight costs, and pressure sentiment around the company’s medical-device portfolio.
• Negative Sentiment: Options activity also turned more cautious, with unusual buying of put options suggesting some traders are positioning for additional downside in BSX.
• Negative Sentiment: Commentary from Jim Cramer added to the bearish tone, saying the sector is “too hard to own” right now and expressing surprise at the decline in Boston Scientific shares.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on BSX shares. Argus raised Boston Scientific to a “strong-buy” rating in a research report on Thursday, February 26th. Wolfe Research downgraded Boston Scientific from an “outperform” rating to a “peer perform” rating in a research report on Friday, May 29th. Oppenheimer set a $90.00 price objective on Boston Scientific in a report on Thursday, April 23rd. Mizuho lowered their price objective on Boston Scientific from $115.00 to $90.00 and set an “outperform” rating on the stock in a research report on Monday, April 13th. Finally, Citigroup reduced their target price on Boston Scientific from $87.00 to $70.00 and set a “buy” rating for the company in a research report on Thursday, May 28th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $83.76.

Boston Scientific Price Performance

The company’s 50 day simple moving average is $53.67 and its two-hundred day simple moving average is $71.70. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. The stock has a market capitalization of $65.90 billion, a P/E ratio of 18.55, a PEG ratio of 0.87 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The business had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $5.19 billion. During the same period in the previous year, the business earned $0.75 EPS. Boston Scientific’s revenue was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, equities analysts expect that Boston Scientific Corporation will post 3.36 EPS for the current fiscal year.

Boston Scientific declared that its Board of Directors has initiated a share buyback program on Monday, May 18th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s management believes its shares are undervalued.

Insider Activity

In related news, Director Cheryl Pegus acquired 1,770 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The stock was purchased at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the transaction, the director directly owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. This trade represents a ? increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Edward J. Ludwig acquired 3,580 shares of Boston Scientific stock in a transaction on Wednesday, May 20th. The shares were purchased at an average cost of $56.68 per share, for a total transaction of $202,914.40. Following the acquisition, the director owned 25,359 shares in the company, valued at approximately $1,437,348.12. This represents a 16.44% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased 9,800 shares of company stock valued at $554,012 over the last three months. 0.34% of the stock is owned by insiders.

Institutional Investors Weigh In On Boston Scientific

A number of institutional investors and hedge funds have recently made changes to their positions in BSX. FWL Investment Management LLC acquired a new stake in Boston Scientific in the second quarter worth about $26,000. Swiss RE Ltd. acquired a new position in Boston Scientific during the 4th quarter valued at about $26,000. Garton & Associates Financial Advisors LLC acquired a new position in Boston Scientific during the 4th quarter valued at about $26,000. Colonial Trust Co SC boosted its stake in shares of Boston Scientific by 502.2% in the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 231 shares during the last quarter. Finally, Bangor Savings Bank grew its position in shares of Boston Scientific by 94.7% during the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 142 shares during the period. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.